CA3222078A1 - O-linked thiadiazolyl compounds as dna polymerase theta inhibitors - Google Patents
O-linked thiadiazolyl compounds as dna polymerase theta inhibitors Download PDFInfo
- Publication number
- CA3222078A1 CA3222078A1 CA3222078A CA3222078A CA3222078A1 CA 3222078 A1 CA3222078 A1 CA 3222078A1 CA 3222078 A CA3222078 A CA 3222078A CA 3222078 A CA3222078 A CA 3222078A CA 3222078 A1 CA3222078 A1 CA 3222078A1
- Authority
- CA
- Canada
- Prior art keywords
- independently selected
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209555P | 2021-06-11 | 2021-06-11 | |
| US63/209,555 | 2021-06-11 | ||
| US202263319826P | 2022-03-15 | 2022-03-15 | |
| US63/319,826 | 2022-03-15 | ||
| PCT/IB2022/055384 WO2022259204A1 (en) | 2021-06-11 | 2022-06-09 | O-linked thiadiazolyl compounds as dna polymerase theta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222078A1 true CA3222078A1 (en) | 2022-12-15 |
Family
ID=82358548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222078A Pending CA3222078A1 (en) | 2021-06-11 | 2022-06-09 | O-linked thiadiazolyl compounds as dna polymerase theta inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240287080A1 (https=) |
| EP (1) | EP4352055A1 (https=) |
| JP (1) | JP2024522373A (https=) |
| KR (1) | KR20240044412A (https=) |
| AU (1) | AU2022289762B2 (https=) |
| BR (1) | BR112023025245A2 (https=) |
| CA (1) | CA3222078A1 (https=) |
| CL (1) | CL2023003671A1 (https=) |
| CO (1) | CO2023017082A2 (https=) |
| IL (1) | IL308912A (https=) |
| MX (1) | MX2023014665A (https=) |
| TW (1) | TW202315618A (https=) |
| WO (1) | WO2022259204A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202623A1 (zh) * | 2022-04-20 | 2023-10-26 | 南京再明医药有限公司 | Polq抑制剂化合物及其应用 |
| AU2023352129A1 (en) * | 2022-09-29 | 2025-05-01 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
| CN117946138A (zh) * | 2022-10-28 | 2024-04-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其中间体、制备方法和应用 |
| WO2024099336A1 (en) * | 2022-11-10 | 2024-05-16 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolyl derivatives, compositions and uses thereof |
| JP2025541823A (ja) * | 2022-12-09 | 2025-12-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー４）、リミテッド | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 |
| WO2024149349A1 (zh) * | 2023-01-14 | 2024-07-18 | 西藏海思科制药有限公司 | 靶向Polθ的化合物及其用途 |
| TW202502745A (zh) * | 2023-02-28 | 2025-01-16 | 美商賽堤爾醫療公司 | ４，５－稠和雙環吡咯啶及４，５－稠和雙環吡咯啶－酮化合物 |
| US12215102B2 (en) * | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| KR20250153866A (ko) | 2023-03-10 | 2025-10-27 | 브레이크포인트 테라퓨틱스 게엠베하 | Dna 중합효소 세타 억제제 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| WO2024213082A1 (en) * | 2023-04-13 | 2024-10-17 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
| CN121712768A (zh) * | 2023-05-30 | 2026-03-20 | 宁波新湾科技发展有限公司 | 噻唑基或噻二唑基酰胺衍生物及其用途 |
| CN121399118A (zh) * | 2023-06-02 | 2026-01-23 | 成都微芯药业有限公司 | Polθ抑制剂及其制备方法和用途 |
| EP4727540A2 (en) * | 2023-06-16 | 2026-04-22 | Quantx Biosciences US, Inc. | Fused bicyclic heterocyclic or hetero aryl amide compounds |
| WO2025011617A1 (zh) * | 2023-07-12 | 2025-01-16 | 杭州圣域生物医药科技有限公司 | 并环杂芳环类化合物、其中间体、制备方法和应用 |
| WO2025016391A1 (zh) * | 2023-07-18 | 2025-01-23 | 南京再明医药有限公司 | 噻唑并吡嗪类化合物及其应用 |
| CN121773109A (zh) * | 2023-07-27 | 2026-03-31 | 北京丹擎医药科技有限公司 | PolQ降解剂及其组合物和应用 |
| WO2025036490A1 (zh) * | 2023-08-17 | 2025-02-20 | 海思科医药集团股份有限公司 | 一种DNA聚合酶θ抑制剂及其用途 |
| KR20260040065A (ko) * | 2023-09-01 | 2026-03-23 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 바이아릴 고리계 화합물, 이의 중간체, 제조 방법 및 용도 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
| WO2025110780A1 (en) * | 2023-11-24 | 2025-05-30 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| WO2025165092A1 (en) * | 2024-01-30 | 2025-08-07 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| CN120829441A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| CN120829442A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| WO2025223483A1 (zh) * | 2024-04-24 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其晶型及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| USRE50319E1 (en) * | 2017-10-16 | 2025-03-04 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| AU2020282768B2 (en) * | 2019-05-31 | 2023-09-14 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as DNA Polymerase Theta inhibitors |
| TW202237595A (zh) * | 2020-12-02 | 2022-10-01 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物 |
-
2022
- 2022-06-08 TW TW111121145A patent/TW202315618A/zh unknown
- 2022-06-09 EP EP22735990.8A patent/EP4352055A1/en active Pending
- 2022-06-09 JP JP2023576009A patent/JP2024522373A/ja active Pending
- 2022-06-09 AU AU2022289762A patent/AU2022289762B2/en active Active
- 2022-06-09 KR KR1020247000980A patent/KR20240044412A/ko active Pending
- 2022-06-09 CA CA3222078A patent/CA3222078A1/en active Pending
- 2022-06-09 MX MX2023014665A patent/MX2023014665A/es unknown
- 2022-06-09 WO PCT/IB2022/055384 patent/WO2022259204A1/en not_active Ceased
- 2022-06-09 IL IL308912A patent/IL308912A/en unknown
- 2022-06-09 US US18/567,687 patent/US20240287080A1/en active Pending
- 2022-06-09 BR BR112023025245A patent/BR112023025245A2/pt unknown
-
2023
- 2023-12-07 CO CONC2023/0017082A patent/CO2023017082A2/es unknown
- 2023-12-07 CL CL2023003671A patent/CL2023003671A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240044412A (ko) | 2024-04-04 |
| AU2022289762A1 (en) | 2023-12-14 |
| US20240287080A1 (en) | 2024-08-29 |
| CL2023003671A1 (es) | 2024-07-12 |
| WO2022259204A1 (en) | 2022-12-15 |
| CO2023017082A2 (es) | 2024-04-18 |
| TW202315618A (zh) | 2023-04-16 |
| EP4352055A1 (en) | 2024-04-17 |
| IL308912A (en) | 2024-01-01 |
| JP2024522373A (ja) | 2024-06-18 |
| BR112023025245A2 (pt) | 2024-02-20 |
| AU2022289762B2 (en) | 2025-12-04 |
| MX2023014665A (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3222078A1 (en) | O-linked thiadiazolyl compounds as dna polymerase theta inhibitors | |
| AU2021390194B2 (en) | Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors | |
| US11840513B2 (en) | Substituted nicotinimide inhibitors of BTK for treating cancer | |
| AU2019246753B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| US10087179B2 (en) | Fused tricyclic imidazole derivatives as modulators of TNF activity | |
| IL297929B1 (en) | Imino sulfanone inhibitors of enpp1 | |
| WO2023067515A1 (en) | Thiadiazolyl compounds as dna polymerase theta inhibitors | |
| CA2935071A1 (en) | Piperidine-dione derivatives | |
| AU2007297212A1 (en) | Pyrido (2, 3-D) pyrimidinone compounds and their use as PI3 inhibitors | |
| JP2018521025A (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| TW202440111A (zh) | 作為ｗｒｎ抑制劑之雜環化合物 | |
| CA3236877A1 (en) | Heterocyclic compounds and uses thereof | |
| CN117794927A (zh) | 作为DNA聚合酶θ抑制剂的O-连接噻二唑基化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |